DETAILED ACTION
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Election/Restrictions
The restriction requirement dated May 11, 2026, has been withdrawn by the examiner.
Claim Rejections - 35 USC § 102
In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status.
The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:
A person shall be entitled to a patent unless –
(a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention.
Claim(s) 1-5, 7, 16, and 22-26 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Staton et al. (WO 2021/102411).
Staton et al. disclose ionizable lipids of formula 46 to formula 51 (pages 52-53). These compounds anticipate the instant claims where L1 and L2 are ethylene, one of Ra and Rb is methyl and the other is HTM, one of Rc and Rd is methyl, and the other is HTM, wherein HTM is a C5-40 alkyl or C5-C40 alkenyl group.
Claim Rejections - 35 USC § 103
The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action:
A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made.
Claim(s) 27-29 is/are rejected under 35 U.S.C. 103 as being unpatentable over Staton et al. (WO 2021/102411) and further in view of Gallagher et al. (WO 2022/016089).
The instant claims further limit the compound of the present invention such that the linear or branched alkyl has one or more intervening groups selected from ester, amide, or carboxylate.
Staton et al. do not specifically teach compounds having the above limitations; however, Gallagher et al. teach ionizable lipids having linkages that contain ester groups prior to hydrophobic tail groups (pages 62-70).
In view of the combined reference teachings, it would have been obvious to a person having ordinary skill in the art that the lipid compounds taught by Staton et al. may be modified to include alkyl groups containing intervening ester groups, attached to hydrophobic tail groups, since Gallagher et al. teach that such linkages afford ionizable lipids that are able to deliver a capsid-free, non-viral DNA vector to a target site of interest, e.g., cell tissue, organs, and the like, the same as the ionizable lipid compounds taught by Staton et al.
Claims 6, 8-15, 17-21, and 30 are objected to as being dependent upon a rejected base claim but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to SIKARL A WITHERSPOON whose telephone number is (571)272-0649. The examiner can normally be reached M-F 9am-9pm IFP.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Scarlett Goon can be reached at 571-270-5241. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/SIKARL A WITHERSPOON/Primary Examiner, Art Unit 1692